AsymBio is the core unit of the newly established strategic business segment within Asymchem Group (Stock Code: 002821.SZ/6821.HK). AsymBio is committed to becoming a technology-driven, one-stop services CDMO company for biologics development/production that can deliver efficient, customizable and extensive high-quality services to our clients. Our all-round and personalized services offer comprehensive capabilities covering process development, product manufacturing, fill-finish, analytical development and testing, domestic and oversea regulatory registration and submission filings for a broad range of novel biopharmaceuticals including antibodies, recombinant biotherapeutics, bioconjugates, plasmids and mRNAs.
AsymBio operates following a flexible and cooperative business model with the motto of “customer-first, quality-first” to achieve win-win outcomes along with our clients. Asymbio is a trusted partner to global innovative biopharmaceutical companies of all sizes, empowering the progress of biopharmaceutical industry with our innovative technologies and platform solutions that are continuously under optimization. We strive to be a partner of choice in global drug R&D and production, starting with every client, every product, and every service.
Cutting-edge technology development and translation for biologics
mAb & ADC development and pilot/commercial production
mAb & ADC late phase and commercial production
Plasmid & mRNA/LNP pilot production
Plasmid & mRNA/LNP late phase and commercial production